Please wait a minute...
http://jcps.bjmu.edu.cn

当期目录

    2025年 第34卷 第10期    刊出日期:2025-11-03
    上一期   
    【综述】
    An overview of the processing, chemical constituents, pharmacological properties, and clinical studies of white tea
    Eric Wei Chiang Chan, Siu Kuin Wong, Hung Tuck Chan
    2025, 34(10):  897-910.  DOI: 10.5246/jcps.2025.10.066
    摘要 ( 12 )   HTML ( 1)  
    数据和表 | 参考文献 | 相关文章 | 计量指标

    This review provided an updated synthesis of current knowledge regarding the processing, chemical constituents, pharmacological properties, and clinical applications of white tea (Camellia sinensis), commonly known as WT. Information was collated from reliable sources, including Google, Google Scholar, PubMed, PubMed Central, Science Direct, PubChem, J-Stage, the Directory of Open Access Journals (DOAJ), and the China National Knowledge Infrastructure (CNKI). In China, WT, referred to as “Bai Cha”, is a prized spring tea harvested during early spring when the young tea plant leaf buds are still covered with delicate, downy white hairs. Fujian Province serves as the primary production region. WT processing is minimal, involving withering as the most crucial step, followed by drying. This simple process preserves its unique qualities and chemical integrity. The dominant phenolic compounds in WT are flavonoids, including catechins, dimeric catechins, flavones, flavonols, and flavanones. Additional constituents encompass phenolic acids, alkaloids, glycosides, and amino acids. These bioactive compounds contribute to WT’s diverse pharmacological properties, including anti-diabetic, anti-cancer, hepatoprotective, neuroprotective, anti-obesity, and male reproductive health benefits. To date, seven clinical studies have investigated the therapeutic potential of WT. These include two studies each on its use as a mouth rinse and its anti-obesity effects, and one study each focusing on its applications in managing diabetes, periodontitis, and depression. Perspectives on WT’s broader implications and opportunities for future research are also explored, highlighting its potential for expanded therapeutic applications.

    【研究论文】
    储存温度对纳米氢氧化铝佐剂质量稳定性的影响
    杨希飞, 张飞伟
    2025, 34(10):  911-920.  DOI: 10.5246/jcps.2025.10.067
    摘要 ( 10 )   HTML ( 3)  
    数据和表 | 参考文献 | 相关文章 | 计量指标

    氢氧化铝佐剂为弱结晶勃姆石(PCB)结构, 该晶体结构受储存条件的影响。本研究旨在揭示佐剂在不同储存温度条件下晶体结构及常规质量指标变化情况。三批氢氧化铝佐剂分别在2–8 ºC、18–25 ºC和37 ºC下储存6个月。检测佐剂的X-射线衍射、pH值、等电点(pI)、吸附率以及平均粒径。X-射线衍射显示佐剂为勃姆石结构。氢氧化铝佐剂在37 ºC下储存1个月, 佐剂衍射图在18.2 º2θ出现新的衍射峰, 并且峰面积随着储存时间而增加。同时佐剂在37 ºC条件下存放pI和pH值下降最明显, 分别为下降0.78和1.33; 当佐剂在2–8 ºC下储存时, 仅在第6个月时, 在18.2 º2θ出现微弱的衍射峰, 表明晶体结构开始发生变化。且pI和pH的下降最少, 分别为0.43和0.80。佐剂的平均粒径为110–140 nm, 因此佐剂具有高蛋白质吸附率, 约8 mg BSA/mg Al3+。在不同温度条件下, 佐剂吸附率差异无统计学意义 (P > 0.05)。纳米氢氧化铝佐剂在整个储存过程中保持较高的吸附能力, 使其成为非凡的疫苗吸附剂。但贮存温度的升高会加速佐剂的老化, 形成高结晶的三水铝石或拜耳石, 不利于佐剂质量稳定性。

    HPLC法测定大鼠血浆中伏立康唑的浓度及其药代动力学研究
    刘晨曦, 刘欢, 陈天萍, 何诗怡, 胡茳玲, 蒋心惠
    2025, 34(10):  921-931.  DOI: 10.5246/jcps.2025.10.068
    摘要 ( 19 )   HTML ( 10)  
    数据和表 | 参考文献 | 相关文章 | 计量指标

    采用高效液相色谱法检测大鼠血浆中伏立康唑的浓度, 并通过内标法进行更为精确的检测和药代动力学研究。以氟康唑为内标, 柱温30 ℃、流动相为甲醇-水梯度洗脱(0~2.5 min: 50%甲醇; 2.5~4 min: 50%~70%甲醇; 4 min后: 70%甲醇)、流速1.0 mL/min、检测波长254 nm、进样20 μL检测。大鼠按40 mg/kg灌胃伏立康唑后, 于不同时间采血, 得到伏立康唑血药浓度, 采用 DAS2.0软件对其进行拟合, 得到其药动学参数。血浆中伏立康唑浓度在0.2~40 mg/L内, 线性关系良好(R2 = 0.9992), 提取回收率大于85%且小于115%, 其日内、日间RSD < 10%。伏立康唑大鼠体内的分布半衰期 t1/2α和消除半衰期t1/2β均为69.315 min, AUC0–t为8040.73 min·mg/L。实验建立的HPLC法简便、快速、准确地测定了伏立康唑在大鼠体内的药物代谢过程, 该方法可用于临床批量检测伏立康唑血样。